Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Nephrology · Steroid-Resistant Nephrotic Syndrome

The Long View: Monitoring, Progression, and Transplantation

At a Glance

In steroid-resistant nephrotic syndrome, monitoring urine protein, kidney function, blood pressure, growth, and bone health helps protect health. Genetic testing matters before transplant because recurrence risk is generally lower in gene-related disease than in presumed primary disease.

Managing Steroid-Resistant Nephrotic Syndrome (SRNS) is a long-term journey. While the initial focus is often on achieving remission, the “marathon” of care involves protecting your kidneys for years to come and, for some, preparing for a kidney transplant. It is important to remember that kidney failure is not inevitable for everyone.

The path forward depends heavily on how your kidneys respond to treatment and whether your condition is monogenic (caused by a gene mutation) or presumed immune-mediated [1][2].

Long-Term Monitoring: The ‘Maintenance’ Phase

Even when the disease is stable, your care team will monitor several “vital signs” of kidney health to prevent long-term complications.

  • Proteinuria & Kidney Function: Your Urine Protein-to-Creatinine Ratio (UPCR) remains the most important predictor of long-term kidney survival [3]. Along with this, your team will track your eGFR (estimated glomerular filtration rate) to ensure the kidneys are still effectively filtering waste [4].
  • Blood Pressure: High blood pressure is very common in SRNS, affecting up to 70% of children with the condition in some studies [5]. Keeping blood pressure in a healthy range is one of the best ways to slow down kidney damage [3].
  • Growth and Bone Health: For children, long-term use of steroids and the disease itself can affect height and bone strength [6]. Doctors will regularly monitor growth velocity and may check Vitamin D levels or bone density to prevent fractures and ensure healthy development [7][3].

Progression to Kidney Failure

For some patients, despite the best available treatments, the kidneys may eventually stop working. This is called End-Stage Renal Disease (ESRD) or kidney failure.

  • Risk Factors: The risk of progression is highest for those who never achieve even a partial remission (a significant drop in protein) [8][2].
  • Survival Rates: These rates depend heavily on the cohort studied and treatment eras. In one large pediatric registry study, about 94% of children who achieved complete remission still had functioning kidneys 10 years later [8]. For those who did not respond to any intensified treatments, that number was lower, around 43% [8]. Patients whose biopsies show a Diffuse Mesangial Sclerosis (DMS) pattern often progress toward kidney failure more rapidly [8].

The Role of Kidney Transplant

A kidney transplant is often the best treatment for ESRD. However, the biggest question for SRNS patients is the “recurrence rate”—the chance of the disease coming back and attacking the new kidney. This is where your genetic status becomes the most important piece of the puzzle.

Type of SRNS Risk of Recurrence Post-Transplant Why?
Presumed Primary (Non-genetic) ~33% to 61% (in selected cohort studies) [9][10] The “circulating factor” in your blood that is suspected of damaging your original kidneys may still be there and may attack the new kidney [10].
Monogenic (Genetic) ~0% to 4.5% (in selected cohort studies) [11][10] The new kidney comes with healthy “blueprints” (genes). Since the problem was a local “blueprint error,” the disease rarely returns [12][13].

One rare exception is NPHS1-associated disease, where the body may create antibodies against the new kidney’s healthy proteins, leading to a recurrence despite the genetic cause [14]. Keep in mind a negative genetic test does not automatically place a patient in the high-risk category, as tests have limitations.

Managing Recurrence

If the disease does return after a transplant, the goal is “rescue” therapy to save the new organ. There is no universal prevention protocol, and these therapies are center-specific with varying levels of evidence.

  • Plasma Exchange (Plasmapheresis): This is often used as a first-line treatment for recurrence. It “washes” the blood to remove the harmful circulating factors [15]. Roughly 71% of patients achieve some level of remission with this approach in certain studies [16].
  • Rituximab: This is often added as a “booster” to plasma exchange if the protein doesn’t disappear quickly [17].
  • Newer Therapies: For very difficult cases, doctors may trial off-label or newer medications like daratumumab or ofatumumab, which target the immune cells producing the harmful factors [18][19].

Whether your path involves long-term medication or preparing for a transplant, the goal remains the same: preserving your quality of life and protecting your kidney function for as long as possible [3].

Common questions in this guide

Does steroid-resistant nephrotic syndrome always cause kidney failure?
No. Some people maintain kidney function for many years, especially when treatment leads to complete or partial remission. Risk is higher when protein loss does not improve with intensified treatment, and a diffuse mesangial sclerosis pattern can be linked with faster progression.
What should be monitored over the long term with SRNS?
The care team usually follows the urine protein-to-creatinine ratio, estimated glomerular filtration rate, and blood pressure to track protein loss and kidney filtering. Children may also need monitoring of growth, vitamin D, and bone density because SRNS and past steroid use can affect development and bone strength.
What is the chance that SRNS will return after a kidney transplant?
The risk depends strongly on whether the disease is presumed primary, meaning non-genetic, or monogenic, meaning caused by a gene change. Selected studies report recurrence of about 33% to 61% for presumed primary SRNS and about 0% to 4.5% for monogenic SRNS, although an individual’s risk can differ and a negative genetic test does not automatically mean high risk.
How is recurrent SRNS treated after a kidney transplant?
Plasma exchange, also called plasmapheresis, is often used first to remove suspected harmful factors from the blood. Rituximab may be added, and difficult cases may be treated with newer or off-label medicines such as daratumumab or ofatumumab; prevention and treatment plans vary by transplant center.
Why does genetic testing matter before a kidney transplant for SRNS?
A genetic cause often means the new kidney does not carry the gene change, so recurrence is less common, while presumed primary disease may recur because a blood-borne factor can affect the transplant. NPHS1-associated disease is a rare exception, and genetic tests have limitations, so results should be reviewed with a nephrologist and transplant team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Idiopathic steroid-resistant nephrotic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on our specific clinical diagnosis and genetic testing, how do you evaluate our risk of the disease coming back after a transplant?
  2. 2.What is the long-term plan for monitoring bone density and growth, especially if we have had high steroid exposure in the past?
  3. 3.If we are moving toward a transplant, what is the transplant center's approach to counseling on recurrence risk and post-op monitoring?
  4. 4.How often should we be checking blood pressure at home between clinic visits?
  5. 5.What are the specific 'transition' milestones we should be aiming for as care moves toward adult nephrology?

References

References (19)
  1. 1

    IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.

    Trautmann A, Vivarelli M, Samuel S, et al.

    Pediatric nephrology (Berlin, Germany) 2020; (35(8)):1529-1561 doi:10.1007/s00467-020-04519-1.

    PMID: 32382828
  2. 2

    Outcomes and prognostic factors in childhood-onset steroid-resistant nephrotic syndrome: a retrospective single-center study.

    Zerkowitz E, Gellermann J, Beckus J, et al.

    Pediatric nephrology (Berlin, Germany) 2025; (40(7)):2239-2252 doi:10.1007/s00467-025-06705-5.

    PMID: 40021511
  3. 3

    Consensus Guidelines on Management of Steroid-Resistant Nephrotic Syndrome.

    Vasudevan A, Thergaonkar R, Mantan M, et al.

    Indian pediatrics 2021; (58(7)):650-666.

    PMID: 33408286
  4. 4

    IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome.

    Hari P, Khandelwal P, Boyer O, et al.

    Pediatric nephrology (Berlin, Germany) 2025; (40(3)):865-872 doi:10.1007/s00467-024-06543-x.

    PMID: 39384644
  5. 5

    Incidence and Risk Factors for Hypertension among Children with Nephrotic Syndrome.

    Robinson C, Wagner S, Aman N, et al.

    The Journal of pediatrics 2025; (284()):114443 doi:10.1016/j.jpeds.2024.114443.

    PMID: 39710174
  6. 6

    Long-term Outcomes of Childhood Onset Nephrotic Syndrome.

    Hjorten R, Anwar Z, Reidy KJ

    Frontiers in pediatrics 2016; (4()):53 doi:10.3389/fped.2016.00053.

    PMID: 27252935
  7. 7

    Nephrotic Syndrome: Current Management.

    Vasudevan A, V H

    Indian journal of pediatrics 2026; (93(5)):507-514 doi:10.1007/s12098-026-06132-w.

    PMID: 41910850
  8. 8

    Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.

    Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al.

    Journal of the American Society of Nephrology : JASN 2017; (28(10)):3055-3065 doi:10.1681/ASN.2016101121.

    PMID: 28566477
  9. 9

    Monogenic variants drive low recurrence risk in pediatric steroid-resistant nephrotic syndrome after kidney transplantation: a high-consanguinity cohort.

    ALQattan F, Azzam A, Alkanani H, et al.

    Pediatric nephrology (Berlin, Germany) 2026; (41(11)):4127-4139 doi:10.1007/s00467-026-07430-3.

    PMID: 42350677
  10. 10

    A Systematic Review and Meta-Analysis of the Rate and Risk Factors for Post-transplant Disease Recurrence in Children With Steroid Resistant Nephrotic Syndrome.

    Morello W, Proverbio E, Puccio G, Montini G

    Kidney international reports 2023; (8(2)):254-264 doi:10.1016/j.ekir.2022.10.030.

    PMID: 36815113
  11. 11

    Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.

    Trautmann A, Bodria M, Ozaltin F, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2015; (10(4)):592-600 doi:10.2215/CJN.06260614.

    PMID: 25635037
  12. 12

    Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome.

    Mason AE, Sen ES, Bierzynska A, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2020; (15(7)):983-994 doi:10.2215/CJN.13371019.

    PMID: 32317330
  13. 13

    Post-transplant recurrence of steroid resistant nephrotic syndrome in children: the Italian experience.

    Morello W, Puvinathan S, Puccio G, et al.

    Journal of nephrology 2020; (33(4)):849-857 doi:10.1007/s40620-019-00660-9.

    PMID: 31617157
  14. 14

    A critical re-analysis of cases of post-transplantation recurrence in genetic nephrotic syndrome.

    Mason AE, Saleem MA, Bierzynska A

    Pediatric nephrology (Berlin, Germany) 2021; (36(11)):3757-3769 doi:10.1007/s00467-021-05134-4.

    PMID: 34031708
  15. 15

    Current approaches to overcome recurrent focal segmental glomerulosclerosis after kidney transplantation.

    Ahmad SB, Peleg Y, Ahn W

    Current opinion in nephrology and hypertension 2024; (33(1)):61-66 doi:10.1097/MNH.0000000000000946.

    PMID: 37921337
  16. 16

    The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series.

    Kashgary A, Sontrop JM, Li L, et al.

    BMC nephrology 2016; (17(1)):104 doi:10.1186/s12882-016-0322-7.

    PMID: 27473582
  17. 17

    Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients.

    Plonsky-Toder M, Pollack S, Tibi R, et al.

    Scientific reports 2024; (14(1)):25493 doi:10.1038/s41598-024-74184-z.

    PMID: 39461970
  18. 18

    Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.

    Angeletti A, Bin S, Magnasco A, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2024; (24(4)):688-692 doi:10.1016/j.ajt.2023.12.010.

    PMID: 38101474
  19. 19

    UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant.

    Reynolds BC, Lamb A, Jones CA, et al.

    Pediatric nephrology (Berlin, Germany) 2022; (37(1)):199-207 doi:10.1007/s00467-021-05248-9.

    PMID: 34383125

This page explains long-term monitoring, kidney failure, and transplant recurrence in steroid-resistant nephrotic syndrome for informational purposes only and does not constitute medical advice. Your nephrologist and transplant team should interpret your genetic results and estimate your personal risk.